MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2026.1918192

Медицинская библиотека · Frontiers in endocrinology · 2026

Non-albumin proteinuria as a candidate biomarker of treatment response to finerenone in diabetic kidney disease: a real-world cohort study.

Choi Min Seo, Kim Hyung Woo, Yu Minheui, Lee Minyoung, Lee Yong-Ho, Kang Eun Seok, Cha Bong-Soo, Lee Byung-Wan

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Finerenone reduces albuminuria and improves kidney outcomes in patients with diabetic kidney disease (DKD); however, its association with changes in non-albumin proteinuria (NAP), enriched for tubular injury-related proteins, remains unclear. We evaluated whether finerenone treatment was associated with a reduction in NAP and identified clinical phenotypes associated with a greater NAP response.

METHODS

We retrospectively analyzed 477 patients treated with finerenone who had baseline urine albumin-to-creatinine ratio (uACR) and urine protein-to-creatinine ratio (uPCR) measurements from the same urine specimen. Urine non-albumin protein-to-creatinine ratio (uNAPCR) was calculated as uPCR minus uACR. Patients were stratified by baseline proteinuria severity (uPCR < 500 vs ≥ 500 mg/gCr). The primary outcome was the geometric mean percentage change in uNAPCR after 6 months of finerenone treatment, assessed using linear mixed-effects models. Subgroup interaction analyses were performed to assess differential associations and identify factors associated with greater uNAPCR reduction.

RESULTS

At baseline, median uPCR, uACR, and uNAPCR were 1140 [580, 2290], 716 [328, 1593], and 410 [223, 700] mg/gCr, respectively. At 6 months, uACR and uNAPCR declined by 30.3% and 17.5%, respectively. Subgroup analyses revealed differential associations: patients with higher baseline proteinuria (uPCR ≥ 500 mg/gCr) showed an 18.8% decline in uNAPCR, whereas those with uPCR < 500 mg/gCr showed a non-significant 1.3% change. Changes in uNAPCR were positively correlated with changes in urine N-acetyl-β-D-glucosaminidase-to-creatinine ratio (uNAGCR) (Spearman's ρ = 0.53; p < 0.001).

DISCUSSION: Finerenone treatment was associated with a reduction in NAP, particularly among patients with higher baseline proteinuria, suggesting a possible effect on tubulointerstitial injury-related processes beyond albuminuria reduction. Prospective multicenter studies are needed to validate uNAPCR as a treatment-response biomarker against clinical endpoints.

Для цитирования: Choi Min Seo, Kim Hyung Woo, Yu Minheui, Lee Minyoung, Lee Yong-Ho, Kang Eun Seok, Cha Bong-Soo, Lee Byung-Wan. Non-albumin proteinuria as a candidate biomarker of treatment response to finerenone in diabetic kidney disease: a real-world cohort study.. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1918192.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.